EXACT Sciences Corp. Hits New 52-Week High at $103.65

EXACT Sciences Corp., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 103.65 on February 23, 2026. This achievement underscores the company's remarkable performance over the past year, with a striking increase of 141.06%, significantly outpacing the S&P 500's growth of 12.95% during the same period. The company's market capitalization stands at approximately USD 19,744 million, reflecting its solid position within the industry. Despite being loss-making, the stock's performance metrics reveal a debt-to-equity ratio of 0.58, indicating a manageable level of debt relative to equity. However, the return on equity is currently at -6.55%, and the price-to-book ratio is noted at 8.22, suggesting that investors are valuing the stock at a premium compared to its book value. As EXACT Sciences Corp. continues to navigate the competitive landscape of the pharmaceuticals and biotechnology industry, this new high marks a pivotal moment in its ongoing journey.